US venture investment lowest in 11 years

19 April 2009

The US venture capital industry continued to contract in the first quarter of the year, new data from Dow Jones VentureSource shows.  Venture capitalists invested just $3.90 billion in US companies in the  quarter, a 50% decline from the nearly $7.78 billion over the same  period in 2008 and the lowest quarterly investment total since 1998.  Only 477 venture deals were completed in the period, well below the 706  deals done in the first quarter last year and the industry's lowest  quarterly deal total since 1996.

"We're seeing continued retrenching in the venture capital industry,"  said Jessica Canning, director of global research for Dow Jones  VentureSource. "Over the past several quarters, VCs have pulled back  significantly on early-stage investments in the USA, across all  industries. During the economic downturn, investors will continue to  focus on nurturing their strongest, existing portfolio companies, and  keep their eyes open for the next set of opportunities."

Health care sees smallest drop

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight